3rd Mitochondria-Related Drug Development

The 3rd Annual Mitochondria-Related Drug Development Summit returns for the first in-person meeting of 80+ industry experts to explore the unique opportunities of targeting mitochondrial dysfunction in rare and prevalent diseases.

This September, unlock the breakthroughs in our understanding of mitochondrial biology, structure, and function, to accelerate drug development. Recent IND approvals and clinical successes prove the near-endless potential of mitochondria to treat cardiovascular, renal, and neurodegenerative diseases.

Join us as we bring together rare mitochondrial disease experts and prevalent disease drug developers for a new era of targeting mitochondrial dysfunction.

URLs:
Brochure: https://go.evvnt.com/1720256-0?pid=10018
Tickets: https://go.evvnt.com/1720256-1?pid=10018
Website: https://go.evvnt.com/1720256-3?pid=10018

Prices:
Full Conference Access - Drug Developer: USD 4096.00,
Conference + 2 Workshops - Drug Developer: USD 3597.00,
Conference + 1 Workshop - Drug Developer: USD 3098.00,
Conference Only - Drug Developer: USD 2599.00,
Full Conference Access - Solution Provider: USD 6046.00,
Conference + 2 Workshops - Solution Provider: USD 5297.00,
Conference + 1 Workshop - Solution Provider: USD 4548.00,
Conference Only - Solution Provider: USD 3799.00

Speakers: Lucy Therapeutics, Colin Exline, Primera Therapeutics, Cynthia Arbeeny, Mitotherapeutix, Daniel Hoeppner, Mitobridge, Danielle Grotjahn, Scripps Research, Janos Steffen, Janssen, John Campbell, Stealth BioTherapeutics, John Lemasters, Medical University of South Carolina, Joseph Brozinick, Eli Lilly and Co, Karel Erion, Capacity Bio, Kenneth Pryde, AstraZeneca, Kira Mann, MitoAction, Klaus Dugi, Vandria, Mark Tarnopolsky, Exerkine Corporation/Stayabove Nutrition, Matthew Kostura, Bantam Pharmaceutical, Nicholas Hertz, Mitokinin, Olivier Van Till, Mitobridge/Nanna Therapeutics, Penelope Andreux, Vandria, Philip Yeske, United Mitochondrial Disease Foundation, Qiutang (Jennifer) Li, Neurophth Therapeutics, Sherine Chan, Neuroene Therapeutics, Spring Behrouz, Vincere Biosciences, Terry Van Vleet, AbbVie, Tong Zhu, Astellas Pharma